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Available online 8 November 2016Background:Healthy athletes demonstrated increased B-type natriuretic peptide (BNP) concentrations following
exercise, but it is unknownwhether these responses are exaggerated in individuals with cardiovascular risk fac-
tors (CVRF) or disease (CVD). We compared exercise-induced increases in BNP between healthy controls (CON)
and individuals with CVRF or CVD. Furthermore, we aimed to identify predictors for BNP responses.
Methods: Serum BNP concentrations were measured in 191 participants (60 ± 12 yrs) of the Nijmegen Marches
before (baseline) and immediately after 4 consecutive days of walking exercise (30–50 km/day). CVRF (n=54)
was deﬁned as hypertension, hypercholesterolemia, obesity or smoking and CVD (n=55) was deﬁned as a his-
tory of myocardial infarction, heart failure, atrial ﬁbrillation or angina pectoris.
Results: Individualswalked 487±79min/day at 65± 10% of theirmaximumheart rate. Baseline BNP concentra-
tions were higher for CVD (median: 28.1 pg/ml; interquartile range: 13–50, p b 0.001) compared to CVRF
(3.9 pg/ml; 0–14) and CON (5.5 pg/ml; 0–14). Post-exercise BNP concentrations were elevated in CVD
(35.7 pg/ml, 17–67, p= 0.01), but not in CVRF participants (p= 0.11) or CON (p= 0.07). No cumulative effect
in BNP concentrations was observed across the consecutive walking days (p N 0.05). Predictors for post-exercise
BNP (R2 = 0.77) were baseline BNP, beta-blocker use and age.
Conclusion: Prolonged moderate-intensity walking exercise increases BNP concentrations in CVD participants,
but not in CVRF and CON. BNP increases were small, and did not accumulate across consecutive days of exercise.
These ﬁndings suggest that prolongedwalking exercise formultiple consecutive days is feasiblewithminimal ef-
fect on myocardial stretch, even for participants with CVD.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Risk factors1. Introduction
B-type natriuretic peptide (BNP) is a hormone that promotes
natriuresis, diuresis and arterial vasodilation and is secreted by
cardiomyocytes in response to myocardial stretch [1]. Since BNP con-
centrations are elevated in subjects with myocardial stress, BNP has
been intensively studied as a circulating biomarker in cardiovascular
diseases. BNP and its cleavage equivalent NT-proBNP have nowadays
become established diagnostic and prognostic biomarkers in cardiovas-
cular medicine [2].y supported by a grant from the
.H.E is supported by a Horizon
ska-Curie Fellowship 655502).
gy (392), Radboud University
therlands.
H. Eijsvogels).
ability and freedom frombias of
land Ltd. This is an open access articlBNP concentrations are known to acutely increase in cardiac patients
undergoing a symptom-limiting exercise test [3,4], with the magnitude
of rise proportional to the degree of myocardial ischemia [5,6]. Other
factors associated with BNP increase include baseline BNP, age, area of
scarred myocardium, change in wall-motion score, workload, lower
resting heart rate and higher percentage of predicted heart rate
achieved [7–9]. Subjects with hypertension [10,11] as well as healthy
controls [12] also showed an increase in BNP after a short bout of high
intensity exercise, with hypertensive subjects showing higher concen-
trations of exercise-induced BNP than controls. Elevations of BNP after
short-duration high-intensity exercise appear to peak immediately
post-exercise and return to baseline within 1 h post-exercise [3,12].
Previous studies revealed that BNPwas also elevated after prolonged
high-intensity exercise (N3–4 h, N80% of maximum heart rate) in
assumingly healthy endurance athletes [13,14]. Age was the main pre-
dictor of the magnitude of the BNP increase [15,16]. The kinetics of
post-exercise BNP concentrations following prolonged exercise show
an increase immediately after intense exercise [15,17–19], with peake under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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turn to baseline concentrations within 3 days [20].
Individuals with cardiovascular diseases (CVD) or risk factors
(CVRF) participate in endurance exercise events more often nowadays
[23,24]. Prolonged moderate-intensity exercise such as walking is typi-
cally performed at 60–70% of themaximumheart rate and appears to be
feasible and attractive for these patients [23,25]. Whether exercise-
induced changes in BNP concentrations after prolonged exercise differ
between CVD or CVRF compared to healthy controls (CON) is unknown.
Therefore, the primary aim of the present study was to compare BNP
concentrations at rest and after a single bout of prolonged moderate-
intensity walking exercise between individuals with CVD, CVRF and
CON. Secondly, we sought to compare post-exercise BNP concentrations
across 4 consecutive days of walking exercise. Thirdly, we aimed to
identify predictors of the exercise-induced increase in BNP concentra-
tions. We hypothesized that individuals with cardiovascular risk factors
and/or disease would show greater changes in BNP after exercise com-
pared to healthy peers due to greater myocardial stress for a similar
bout of exercise. Furthermore, we speculated that BNP concentrations
show a cumulative effect over the four subsequent walking days, be-
cause previous studies demonstrated peak BNP concentrations at
1 day post-exercise [20–22].
2. Methods
2.1. Study population
This was an observational cohort study. A selection of participants of
the 2014 and 2015 edition of the Nijmegen Four Days Marches were in-
vited to participate in our study. The Four Days Marches is the largest
multiple day walking event in the world (http://www.4daagse.nl/en/).
Participants of the Nijmegen Marches walked 30, 40 or 50 km per day
for 4 consecutive days. Participants could self-select their distance,
pace and timing of breaks during walking. CVD, CVRF and CON partici-
pants were recruited via social media and the website of the Nijmegen
Marches. CVRF was deﬁned as hypertension, hypercholesterolemia,
obesity or smoking. CVD was deﬁned as a history of myocardial infarc-
tion, heart failure, atrial ﬁbrillation or angina pectoris. Participants
were allowed to havemultiple diagnoses, but could only be part of a sin-
gle group. Therefore, if a participantwith CVRF also had CVD, onewould
be allocated to the CVD group. Healthy controls were free from CVRF
and CVD. The medical ethical committee of the Radboud University
Medical Center approved the study and all participants provided writ-
ten informed consent before participation. The study was conducted
in line with the Declaration of Helsinki.
2.2. Study procedures
Participants completed an extensive questionnaire including general
demographic data, walking distance and detailed questions on their
(cardiovascular) health status. One or two days before the start of the
event (i.e. baseline), body weight (Seca 888 Scale, Seca, Hamburg,
Germany) and height were measured. In addition, heart rate and
blood pressure at rest weremeasured using an automated sphygmoma-
nometer (M5-1 Intellisense, Omron Health Care, Hoofddorp, The
Netherlands) after 5 min of supine rest. Furthermore, at baseline and
~10 min after the ﬁnish on each walking day (day 1–4), a venous
blood sample (10 mL) was drawn from an antecubital vein. Blood sam-
ples were collected in serum-gel Vacutainer tubes and allowed to clot
for ~45 min. After centrifugation, serum was aliquoted, frozen, and
stored at−80 °C for later analysis. BNP concentrations were analyzed
using a high sensitive BNP assay (Centaur BNP, Siemens Healthcare Di-
agnostics, The Hague, The Netherlands), with a detection limit of
2 pg/mL and a coefﬁcient of variation of 20% at 2.5 pg/mL, 4.7% at
30 pg/mL, and 2.3% at 1500 pg/mL. Start and ﬁnish times were used to
determine exercise duration and walking speed. Heart rate wasrecorded during the ﬁrst exercise day with a 2-channel electrocardio-
graphic chest band system (Polar Electro Oy, Kempele, Finland) and
measured with a data recorder every 5 km along the route. Exercise in-
tensity was calculated as average heart rate during exercise divided by
estimated maximum heart rate (208 − 0.7 × age) [26]. An overview
of all measurements is presented in Fig. 1. Safety of the participants
was secured by multiple medical assistance places along the walking
route.
2.3. Data analysis
Statistical analyses were performed using SPSS Statistics 21 (SPSS,
Inc., Chicago, Illinois). Continuous variables were reported as mean ±
SD or median (interquartile range) and categorical variables as propor-
tions. BNP concentrations at baseline and post-exercise were trans-
formed with the natural logarithm as Ln (BNP concentration + 2)
prior to statistical analysis. Change in BNP (ΔBNP), was deﬁned as
Ln(BNP post-exercise + 2) − Ln (baseline BNP + 2). One-way
ANOVA was used to compare baseline characteristics across groups.
Pearson Chi-Square tests were used to compare categorical variables
and a post-hoc z-test comparison of columnswith Bonferroni correction
was done in case of statistical signiﬁcance. To assess aim 1 and 2, one-
way repeated measures ANOVA was used to compare the acute and
prolonged effect of exercise on BNP concentrations between CON,
CVRF and CVD participants. Bonferroni was used as post-hoc test in
case of statistical signiﬁcance. To assess aim 3, linear regression analysis
was used to identify predictors of post-exercise BNP and ΔBNP. First,
univariate linear regression analysis of variables was used to select po-
tential predictors for multivariate analysis. Variables that were signiﬁ-
cantly associated with BNP concentrations using univariate analysis
were then included in a multivariate analysis. We performed a back-
ward multivariate linear regression analysis to gain insight in which
variables could independently predict post-exercise BNP and ΔBNP.
Statistical signiﬁcance was assumed at p b 0.05.
3. Results
Our cohort consisted of n= 83 healthy individuals, n= 53 individ-
uals with CVRF, and n=55 individualswith CVD. Participant character-
istics are summarized in Table 1. One CON participant dropped out after
day 1, whereas no BNP concentration could be determined in 6 samples
of participants on one of the walking days due to insufﬁcient sample
volume. On average, participants walked 487 ± 79 min/day at 65 ±
10% of their predicted maximum heart rate (Table 1).
Compared to CVRF participants and CON, participants with CVD
were older, more oftenmen, had lower diastolic blood pressure, walked
at a lower exercise intensity and more frequently used medication.
Compared to CVRF participants, the CVD group had lower mean and
systolic blood pressures. Furthermore, compared with CON, the CVD
group had a larger height, higher weight, higher BMI and slower walk-
ing speed. Whereas compared to CON, CVRF participants were more
often men and had a higher mean weight and BMI (Table 1).
3.1. Effects of exercise on BNP concentrations.
Baseline BNP concentrations were signiﬁcantly higher in CVD
(28.1 pg/ml; 13–50, p b 0.001) compared to CVRF participants
(3.9 pg/ml; 0–14) and CON (5.5 pg/ml; 0–14) (Fig. 2). At baseline, six
participants (3%, all CVD) had a BNP concentration N 100 pg/ml. Post-
exercise BNP concentrations (day 1: 35.7 pg/ml, 17–67) were signiﬁ-
cantly (p= 0.01) elevated in CVD participants, but not in CVRF partici-
pants (8.2 pg/ml, 0–14, p= 0.11) or CON (5.2 pg/ml, 0–14, p= 0.07).
Seven (4%, all CVD) participants had a BNP concentration N 100 pg/ml
after day 1 of walking exercise. Post-exercise BNP concentrations at
day 2 to 4 were not different compared to post-exercise levels found
on day 1 for any of the groups (p N 0.05).
Fig. 1. Flowchart indicating study phase and accompanying measurements.
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Univariate analysis revealed that age, sex, walking distance, walk-
ing duration, walking speed, exercise intensity, baseline BNP, study
group (CON, CVRF, CVD), the use of beta-blockers, angiotensin-
converting enzyme/angiotensin II/renin inhibitors, mineralocorticoid
antagonist, diuretics, statins and anticoagulants were signiﬁcantly pos-
itively associated with post-exercise BNP concentrations (Table 2). Be-
cause of multicollinearity, walking duration was excluded from
multivariate analysis based on its lowest R2 with univariate analysis.
Multivariate analysis revealed that baseline BNP, beta-blocker use
and age signiﬁcantly predict post-exercise BNP (R2 = 0.77) (Table 3).
Baseline BNP and beta-blocker use were signiﬁcantly associated with
ΔBNP in both univariate and multivariate analysis (R2 = 0.18;
Tables 2 & 3).Table 1
Baseline cohort characteristics.
Cohort characteristics Total Controls
N 191 82
Age, years 60 ± 12 56 ± 13
Sex, male, n (%) 123 (64) 36 (44)
Female, n (%) 68 (36) 46 (56)
Height, cm 174 ± 8 172 ± 8
Weight, kg 79 ± 15 73 ± 12
BMI, kg/m2 25.8 ± 3.5 24.4 ±
Mean BP, mm Hg 101 ± 12 100 ± 1
Systolic BP, mm Hg 136 ± 17 135 ± 1
Diastolic BP, mm Hg 83 ± 10 83 ± 10
Walking distance
30 km, n (%) 79 (41) 24 (29)
40 km, n (%) 93 (49) 48 (59)
50 km, n (%) 19 (10) 10 (12)
Walking duration, min 487 ± 79 491 ± 7
Walking speed, km/h 4.6 ± 0.7 4.7 ± 0
Rest HR 65 ± 9 65 ± 8
Exercise intensity, (%HRmax) 65 ± 10 67 ± 9
CVRF, n (%) 92 (48) –
Hypertension, n (%) 43 (23) –
Hypercholesterolemia, n (%) 43 (23) –
Obesity (BMI N 30), n (%) 22 (12) –
Smoking (current), n (%) 9 (5) –
CVD, n (%) 55 (29) –
Myocardial infarction, n (%) 31 (16) –
Angina pectoris, n (%) 24 (13) –
Heart Failure, n (%) 20 (11) –
Atrial ﬁbrillation, n (%) 19 (10) –
Cardiovascular medication use, n (%) 76 (40) 0 (0)
Beta-blocker, n (%) 45 (24) 0 (0)
Calcium antagonist, n (%) 10 (5) 0 (0)
ACE/AT2/Renin inhibitor, n (%) 46 (24) 0 (0)
Anticoagulants, n (%) 54 (28) 0 (0)
Statin, n (%) 54 (28) 0 (0)
Diuretic, n (%) 21 (11) 0 (0)
Antimineralocorticoid, n (%) 3 (2) 0 (0)
Data are presented as mean ± standard deviation or frequency (%). Continuous variables we
Chi-squared tests. CVD = cardiovascular disease, BMI = body mass index, HR = heart rate. ⁎
AT2 = angiotensin-converting enzyme/angiotensin 2.4. Discussion
Our results indicate that ~8 h ofmoderate intensitywalking exercise
cause a mild but signiﬁcant increase in post-exercise BNP concentra-
tions in CVD participants, but not in CVRF participants or CON. In
addition, bouts of prolonged walking on subsequent days did not result
in a further increase in BNP concentrations. We also found that baseline
BNP concentrations, beta-blocker use and age independently predicted
post-exercise concentrations, whereas baseline BNP concentrations and
beta-blocker use predicted ΔBNP concentrations.
4.1. Acute effects of exercise
Participantswith CVDdemonstrated higher baseline BNP concentra-
tions compared to CON and CVRF, which is in line with literature [27].CVRF CVD p-Value
54 55
60 ± 10 67 ± 7†⁎ 0.000
36 (67)† 51 (93)†⁎
18 (33) 4 (7)
175 ± 9 177 ± 6† 0.007
83 ± 18† 84 ± 11† 0.000
2.8 26.7 ± 4.0† 26.9 ± 3.3† 0.000
2 105 ± 13 97 ± 11⁎ 0.001
7 142 ± 19 133 ± 16⁎ 0.02
87 ± 11 79 ± 10†⁎ 0.000
0.000
18 (33) 37 (67)⁎†
28 (52) 17 (31)†
8 (15) 1 (2)⁎
5 503 ± 98 465 ± 57⁎ 0.04
.7 4.6 ± 0.7 4.3 ± 0.6† 0.01
66 ± 9 63 ± 10 0.38
68 ± 10 60 ± 9⁎† 0.000
54 (100) 39 (71) –
21 (40) 22 (40) –
16 (30) 27 (49) –
13 (24) 9 (16) –
8 (15) 1 (2) –
– 55 (100) –
– 31 (56) –
– 24 (44) –
– 20 (36) –
– 19 (35) –
23 (43)† 53 (96)⁎† 0.000
6 (11)† 39 (71)⁎† 0.000
3 (6) 7 (13)† 0.01
5 (9)† 41 (75)⁎† 0.000
6 (11)† 48 (87)⁎† 0.000
11 (20)† 43 (78)⁎† 0.000
7 (13)† 14 (26)† 0.000
0 (0) 3 (6)† 0.03
re compared using one-way ANOVA; categorical variables were compared using Pearson
= signiﬁcantly different from CVRF group, † = signiﬁcantly different from controls. ACE/
b
a
s
e
li
n
e
d
a
y
 1
d
a
y
 2
d
a
y
 3
d
a
y
 4
b
a
s
e
 l
in
e
d
a
y
 1
d
a
y
 2
d
a
y
 3
d
a
y
 4
b
a
s
e
 l
in
e
d
a
y
 1
d
a
y
 2
d
a
y
 3
d
a
y
 4
0
20
40
60
80
B
N
P
 
(
p
g
/
m
l
)
CVD
CVRF
CON p=.01* 
 p=.24  p=.61  p=.11  p=.07 
  p=.42 
  p=1.00 
p<.001* 
Fig. 2. B-type Natriuretic Peptide (BNP) concentrations at baseline and after prolonged
walking exercise on days 1–4 for controls (CON), participants with risk factors (CVRF)
and participants with cardiovascular diseases (CVD); BNP concentrations displayed as
median with interquartile range. * = p b 0.05.
Table 3
Multivariate linear regression analysis.
Prediction model B (CI) p-Value
Post-exercise BNP R2 = 0.77
Baseline BNP 0.71 (0.62–0.80) 0.00
Beta-blocker use 0.56 (0.33–0.78) 0.00
Age, years 0.01 (0.00–0.02) 0.02
ΔBNP R2 = 0.18
Baseline BNP −0.23 (−0.31–−0.15) 0.00
Beta-blocker use 0.56 (0.33–0.79) 0.00
433V.L. Aengevaeren et al. / International Journal of Cardiology 227 (2017) 430–435More importantly, we found that prolonged walking exercise produced
a subtle but signiﬁcant increase in BNP concentrations in CVD partici-
pants only. The lack of BNP increase in CON and CVRF is in contrast
with previous studies that assessed exercise-induced changes in BNP
concentrations in athletic populations [15,17,18]. A potential explana-
tion for these discrepant ﬁndings may relate to the intensity of
the exercise bout. Whereas previous studies performed exercise at a
high-intensity (N80% HRmax) [8,15,17], our participants performed
moderate-intensity prolonged walking exercise at 65 ± 10% of their
predictedmaximumheart rate. Indeed, exercise intensitywas previous-
ly established as a contributor to the magnitude of BNP release [8]. The
CVD group showed an increase in BNP, although their exercise intensity
was lower (60 ± 9%) compared to the other groups. Use of beta-Table 2
Univariate linear regression analysis of cohort characteristics.
Cohort characteristics
Post-exercise BNP
B (CI) R2
Age, years 0.06 (0.04–0.07) 0.28
Sex, male −0.71 (−1.07–−0.35) 0.08
Height, cm 0.02 (−0.004–0.04) 0.01
Weight, kg 0.01 (−0.003–0.02) 0.01
BMI, kg/m2 0.03 (−0.02–0.08) 0.01
Mean BP, mm Hg −0.01 (−0.03–0.01) 0.01
Systolic BP, mm Hg −0.003 (−0.01–0.01) 0.002
Diastolic BP, mm Hg −0.02 (−0.03–0.001) 0.02
Walking distance,
30 km ref. 0 0.19
40 km −0.96 (−1.30–−0.62) –
50 km −1.52 (−2.08–−0.95) –
Walking duration, min −0.003 (−0.005–−0.001) 0.04
Walking speed, km/h −0.51 (−0.75–−0.26) 0.08
Rest HR −0.01 (−0.03–0.01) 0.01
Heart rate/max heart rate, % −0.04 (−0.06–−0.03) 0.13
Ln baseline BNP 0.85 (0.78–0.93) 0.73
Cardiovascular health,
CON ref. – 0.25
CVRF -0.57 (−0.95 – -0.18) –
CVD 1.55 (1.23–1.87) –
Medication use 0.89 (0.56–1.22) 0.13
Beta-blockers 1.56 (1.21–1.91) 0.30
Calcium antagonist 0.74 (−0.04–1.53) 0.02
ACE/AT2/renin inhibitor 1.50 (1.15–1.85) 0.28
Antimineralocorticoid 1.61 (0.21–3.01) 0.03
Diuretics 0.69 (0.12–1.26) 0.03
Statin 1.16 (0.80–1.52) 0.18
Anticoagulants 1.32 (0.98–1.67) 0.24
⁎= p b 0.05, signiﬁcant univariate predictor. CI=Conﬁdence Interval; BMI=bodymass index (
CON = controls; CVRF = Cardiovascular risk factors; CVD = cardiovascular disease; ref. = refblockers is a likely explanation for this observation. Besides lowering
the maximum attained heart rate, beta-blocker use may independently
increase exercise-induced BNP concentrations [9]. For CON and CVRF,
prolonged moderate-intensity walking exercise may induce a lower,
or absent, increase in BNP concentration following exercise.
4.2. Effect of repetitive bouts of exercise
BNP concentrations did not further increase after the ﬁrst day of
prolonged walking exercise. This ﬁnding was unexpected considering
previous observations in marathon runners, who demonstrated peak
BNP concentrations N 24 h post-exercise [20–22]. It was hypothesized
that the delayed BNP peak previously found could point towards
transient myocardial dysfunction [20]. However, we previously
demonstrated that CVDparticipants demonstrate no signs of (transient)
myocardial dysfunction after prolonged walking exercise [28]. An alter-
native explanation for the lack of accumulation may relate to the short
half-life time of BNP (~20min), whichwould cause BNP concentrations
to drop back to baseline before initiation of exercise on day 2–4.ΔBNP
p-Value B (CI) R2 p-Value
0.000⁎ 0.001 (−0.007–0.009) 0.00 0.76
0.000⁎ −0.19 (−0.38–0.01) 0.02 0.07
0.12 0.01 (−0.003–0.02) 0.01 0.14
0.13 0.01 (−0.001–0.01) 0.02 0.09
0.23 0.02 (−0.01–0.05) 0.01 0.12
0.18 -0.001 (−0.01–0.01) 0.001 0.76
0.55 -0.002 (−0.01–0.003) 0.004 0.39
0.07 0.001 (−0.01–0.01) 0.00 0.83
0.000⁎ 0 0.01 0.42
0.000⁎ -0.05 (−0.25–0.16) – 0.65
0.000⁎ 0.18 (−0.16–0.51) – 0.31
0.01⁎ 0.001 (0.00–0.002) 0.02 0.09
0.000⁎ -0.09 (−0.22–0.05) 0.01 0.22
0.25 0.002 (−0.01–0.01) 0.001 0.71
0.000⁎ −0.004 (−0.01–0.01) 0.003 0.48
0.000⁎ −0.15 (−0.22–−0.07) 0.07 0.000⁎
0.000⁎ – 0.002 0.50
0.004 0.06 (−0.16–0.27) – 0.60
0.000⁎ 0.04 (−0.17–0.25) – 0.72
0.000⁎ 0.08 (−0.11–0.27) 0.004 0.42
0.000⁎ 0.26 (0.04–0.48) 0.03 0.02⁎
0.06 0.02 (−0.40–0.44) 0.00 0.93
0.000⁎ 0.11 (−0.11–0.33) 0.005 0.34
0.02⁎ 0.36 (−0.40–1.11) 0.005 0.35
0.02⁎ −0.17 (−0.48–0.13) 0.007 0.27
0.000⁎ 0.11 (−0.10–0.32) 0.006 0.30
0.000⁎ 0.09 (−0.13–0.30) 0.003 0.43
weight/length2); BP=bloodpressure;HR=heart rate; BNP=B-typenatriuretic peptide;
erence group.; ACE/AT2 = Angiotensin-converting enzyme/Angiotensin 2.
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leading to comparable post-exercise BNP concentrations. This hypothe-
sis is in contrastwith previous literature on BNP kinetics after prolonged
high intensity exercise, suggesting that the exercise intensity may
change BNP kinetics. However, it aligns with previous observations on
BNP kinetics after short-term high-intensity exercise [3,12]. This sug-
gests BNP kinetics may be inﬂuenced by a combination of both exercise
intensity and duration, and that exercise bouts may need to be both
long-term and of high intensity to induce prolonged elevations in BNP
concentrations.
4.3. Predictors of BNP
Baseline BNP, beta-blocker use and age predicted post-exercise BNP
concentrations in a positively correlated fashion. These ﬁndings are con-
sistentwith previous studies on predictors of post-exercise BNP concen-
trations [7–9,15,16]. The exercise-induced increase in BNP (ΔBNP) was
predicted by baseline BNP and beta-blocker use in our multivariate lin-
ear regression model. Interestingly, we found baseline BNP to be nega-
tively associated with ΔBNP. This was an unexpected ﬁnding [8] and
may be explained by the heterogeneous ﬁtness levels of CVD partici-
pants that were included in the present study. Our data suggest that
lower baseline BNP concentrations may represent ﬁtter CVD partici-
pants who are able to exercise at a higher intensity and therefore have
greaterΔBNP compared to less ﬁt CVD participants with higher baseline
BNP concentrations. Nonetheless, the contribution of baseline BNP to
predict ΔBNP was low (7%) and appears to be of little clinical signiﬁ-
cance. More importantly, baseline BNP concentrations were tightly cor-
related to post-exercise BNP concentrations (R2 = 0.73, p b 0.001),
indicating that the relative change in BNP was rather small. However,
this resulted in the excellent predictability of post-exercise BNP using
our multivariate model.
4.4. Limitations
The strengths of the present study are its large sample size and the
inclusion of a cardiovascular patient population that performed endur-
ance exercise. The limitations include that we allowed self-selected dis-
tance and pace and did not match the groups for age and other baseline
characteristics. Nevertheless, these parameters were included in the
univariate and multivariable adjusted regression analyses, to establish
predictors of exercise-induced BNP release. Moreover, we did not
match or select people based on level of physical ﬁtness. Another poten-
tial limitation may be the timing of our blood drawing. We obtained
blood samples typically b10 min post-exercise. Although the half-life
time of BNP is considered ~20min, the time of blood samplingwas sim-
ilar across all days and study groups and aligns with a previous ﬁeld
based study [18]. Finally, we only measured BNP and not its cleavage
equivalent NT-proBNP. Given the different exercise-induced kinetics
[20] of both biomarkers, it is unfortunately not possible to compare
our ﬁndings with previous research on NT-proBNP.
4.5. Conclusion
In conclusion, prolonged moderate-intensity walking exercise in-
duces a mild but signiﬁcant increase in BNP concentrations in individ-
uals with CVD, but not in individuals with CVRF and CON. Walking for
consecutive days did not further increase BNP concentrations after the
ﬁrst day of prolonged walking. Post-exercise BNP concentrations can
be well predicted as baseline BNP, beta-blocker use and age can explain
77% of its variance. ΔBNP is hard to predict, as baseline BNP and beta-
blocker use only explain 18% of ΔBNP variance. Overall, these ﬁndings
suggest that prolonged walking exercise for multiple consecutive days
is feasible with minimal effect on myocardial stretch, even for partici-
pants with CVD.Conﬂicts of interest
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